The Precision Peptide Company Inc. Notes Draft HHS Peptide Policy
A draft HHS policy describes enforcement discretion for compounding six peptides under 503A, including non-injectable routes for BPC-157. The company is evaluating with its…
DO
By Daniel Okafor · Regulatory Correspondent
Nov 3 07:00 ETSource: TradingView
From the source
Read at tradingview.comThe Precision Peptide Company Inc. Notes Draft HHS Peptide Policy
A draft HHS policy describes enforcement discretion for compounding six peptides under 503A, including non-injectable routes for BPC-157. The company is evaluating with its compounding partner how the policy may apply to its prescription formulary.
